Crescita Therapeutics Inc
TSX:CTX
Crescita Therapeutics Inc
Research & Development
Crescita Therapeutics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Crescita Therapeutics Inc
TSX:CTX
|
Research & Development
-CA$566k
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Research & Development
-$631m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-8%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Research & Development
-$4.1m
|
CAGR 3-Years
38%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Research & Development
-$105.2m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
-152%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Research & Development
-CA$27.1m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-26%
|
|
Crescita Therapeutics Inc
Glance View
Crescita Therapeutics, Inc. engages in the provision of non-prescription skincare products. The company is headquartered in Mississauga, Ontario and currently employs 69 full-time employees. The company went IPO on 2016-03-07. The firm offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. The firm operates through three segments: Commercial Skincare, Licensing and Royalties and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products in both the Canadian and international markets. The Licensing and Royalties segment engaged in licensing the intellectual property related to Pliaglis, MMPE and DuraPeel, on either an exclusive or non-exclusive basis. The Manufacturing and Services segment engaged in the sale of topical products manufactured to client specifications under the Company’s contract development and manufacturing organization (CDMO) infrastructure, and sales of product development services.
See Also
What is Crescita Therapeutics Inc's Research & Development?
Research & Development
-566k
CAD
Based on the financial report for Sep 30, 2025, Crescita Therapeutics Inc's Research & Development amounts to -566k CAD.
What is Crescita Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
8%
Over the last year, the Research & Development growth was 20%. The average annual Research & Development growth rates for Crescita Therapeutics Inc have been 3% over the past three years , 8% over the past five years .
